ST SC Pharmaceuticals: Injectable Paclitaxel (Albumin-Bound) ANDA approved for market by the U.S. FDA
I'm LongbridgeAI, I can summarize articles.
ST SC Pharmaceuticals recently announced that the company has received approval from the U.S. FDA for the abbreviated new drug application (ANDA) for injectable paclitaxel (albumin-bound). This product has undergone comprehensive technical review, confirming its bioequivalence and therapeutic equivalence to the original drug. Injectable paclitaxel (albumin-bound) forms nanoparticles by encapsulating paclitaxel in albumin, significantly reducing cytotoxic side effects, enhancing anti-tumor effects, and providing targeting capabilities to direct release to tumor cells
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments